Prostate cancer risk and aggressiveness associated with the CYPIB1 4326C/G （Leu432Val） polymorphism： a meta-analysis of 2788 cases and 2968 controls

To derive a precise estimation of the associations between the cytochrome P450 1B 1 （CYPIB1） 4326C/G variants and prostate cancer （PCa） risk or aggressiveness, a meta-analysis was performed using all eligible published studies. Odds ratios （ORs） with 95% confidence intervals （CIs） were estimated to assess the association in seven literature studies with 2788 cases and 2968 controls. In the overall analysis, no significant association was found between the CYPIB1 4326C/G polymorphism and PCa risk, but ethnicity subgroup analyses and a case-source analysis revealed significant associations. The 4326G allele showed a significant association with increased PCa risk in Asians （OR= 1.52, 95% Ch 1.20-1.92）, and significant associations were also observed in a heterozygote comparison （OR= 1.40, 95% Ch 1.03-1.89）, a homozygote comparison （0R=2.38, 95% Ch 1.31-4.33） and in a dominant genetic model （OR = 1.52, 95% Ch 1.14-2.01）. Moreover, the 4326G allele was also significantly correlated with an increased risk of sporadic PCa （OR= 1.13, 95% Ch 1.04-1.24）, and significant associations were observed in a heterozygote comparison （OR= 1.16, 95% Ch 1.02-1.33）, a homozygote comparison （OR= 1.24, 95% Ch 1.03-1.49） and a dominant genetic model （OR= 1.19, 95% Ch 1.05- 1.34）. The overall analyses and all subgroup analyses showed no significant association between the 4326C/G polymorphism and PCa aggressiveness. Our meta-analysis showed that CYPIB1 4326G allele is significantly associated with an increased PCa risk in Asians and in sporadic PCa cases.

Glutathione S-transferase M1 polymorphism and esophagealcancer risk:An updated meta-analysis based on 37 studies

AIM: To evaluate the relationship between glutathione S-transferase M1(GSTM1) polymorphism and susceptibility to esophageal cancer(EC).METHODS: A comprehensive search of the United States National Library of Medicine Pub Med database and the Elsevier, Springer, and China National Knowledge Infrastructure databases for all relevant studies was conducted using combinations of the following terms: "glutathione S-transferase M1", "GSTM1", "polymorphism", and "EC"(until November 1, 2014). The statistical analysis was performed using the SAS software(v.9.1.3; SAS Institute, Cary, NC, United States) and the Review Manager software(v.5.0; Oxford, England); crude odds ratios(ORs) with 95% confidence intervals(CIs) were used to assess the association between the GSTM1 null genotype and the risk of EC.RESULTS: A total of 37 studies involving 2236 EC cases and 3243 controls were included in this metaanalysis. We observed that the GSTM1 null genotype was a significant risk factor for EC in most populations(OR = 1.33, 95%CI: 1.12-1.57, P_(heterogeneity) < 0.000001, and I2 = 77.0%), particularly in the Asian population(OR = 1.53, 95%CI: 1.26-1.86, P_(heterogeneity)< 0.000001, and I2 = 77.0%), but not in the Caucasian population(OR = 1.02, 95%CI: 0.87-1.19, P_(heterogeneity) = 0.97, and I2 = 0%).CONCLUSION: The GSTM1 null polymorphism may be associated with an increased risk for EC in Asian but not Caucasian populations.

XRCC1 genetic polymorphism Arg399Gln and gastric cancer risk:A meta-analysis

AIM： To evaluate the association between X-ray crosscomplementing gene 1 （XRCCl） genetic polymorphism Arg399Gln and gastric cancer risk by means of metaanalysis. METHODS： We searched PubMed and NCBI up to June 1, 2008. A total of 16 clinical trials and reports were identified, but only 8 trials qualified under our selection criteria. Statistical analysis was performed with the software program Review Manage, version 4.2.8. RESULTS： Of the 8 case-control studies selected for this meta-analysis, a total of 1334 gastric cancer cases and 2194 controls were included. For Arg399GIn, the Gin/Gin genotype carriers did not have a decreased cancer risk compared with those individuals with the Arg/Arg genotype （OR = 0.92, 95% CI, 0.71-1.19; P = 0.51）. Similarly, no associations were found in the recessive and dominant modeling （Gin/Gin vs Arg/GIn ＋ Arg/Arg： OR = 0.96; 95% CI, 0.77-1.19; P = 0.70 and Gin/Gin ＋ Arg/GIn vs Arg/Arg： OR = 0.90, 95% CI, 0.77-1.05; P = 0.18）. CONCLUSION： No association is found between the XRCC1 polymorphism Arg399GIn and gastric cancer risk.

CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk:A meta-analysis

AIM:To study the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by meta-analysis. METHODS:A meta-analysis was performed to investigate the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by reviewing the related studies until September 2010.Data were extracted and analyzed.Crude odds ratio(OR) with 95% confidence interval(CI) was used to assess the strength of relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk. RESULTS:Thirteen published case-control studies including 5336 cases and 6226 controls were acquired. The pooled OR with 95%CI indicated that CYP1A1 Ile462Val polymorphism was significantly related with colorectal cancer risk(Val/Val vs Ile/Ile:OR=1.47,95%CI:1.16-1.86,P=0.002;dominant model:OR= 1.33,95%CI:1.01-1.75,P=0.04;recessive model:OR=1.49,95%CI:1.18-1.88,P=0.0009) .Subgroup ethnicity analysis showed that CYP1A1 Ile462Val polymorphism was also significantly related with colorectal cancer risk in Europeans(Ile/Val vs Ile/Ile:OR=1.22,95%CI:1.05-1.42,P=0.008;dominant model:OR= 1.24,95%CI:1.07-1.43,P=0.004) and Asians(Val/ Val vs Ile/Ile:OR=1.40,95%CI:1.07-1.82,P=0.01;recessive model:OR=1.46,95%CI:1.12-1.89,P= 0.005) . CONCLUSION:CYP1A1 Ile462Val may be an increased risk factor for colorectal cancer.

Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer

Objective:To investigate association between glutathione S-transferases(GSTs) and cervical cancer.Methods:Published literature from PubMed,EMBASE,and other databases were retrieved.All studies evaluating the association between GSTM l/GSTTl polymorphisms and cervical were included.Pooled odds ratio(OR) and 95%confidence interval(CI) were calculated using fixed- or random-effects model.Results:A total of 15 case-control studies were included in the meta-analysis of GSTM1 genotypes(1825 cases and 2 104 controls).The overall result showed that the association between GSTM 1 null genotype and risk for cervical cancer was statistically significant(OR= 1.53,95%CI= 1.18-2.00).Great heterogeneity was found between studies.Subgroup analysises were performed based on smoking and ethnicity.Our results showed that smokers with null CSTM1 genotype had higher risk of cervical cancer(0R=1.56,95%CI=l.01- 2.41).For the ethnicity stratification,significant increased risk of null GSTM1 genotype was found in Chinese and Indian population,but no increased risk in other population.Conclusions:This meta-analysis provides strong evidence that the GSTM1 null genotype is associated with the development of cervical cancer,and especially in Chinese and Indian population,and smoking shows a modification on the association between GSTM 1 null genotype and cervical cancer.

Association between esophageal cancer risk and EPHX1 polymorphisms:A meta-analysis

AIM: To summarize the relationship between p.Tyr113His and p.His139Arg polymorphisms in microsomal epoxide hydrolase (EPHX1) and risk for esophageal cancer (EC).

XRCC1 Polymorphisms and Pancreatic Cancer:A Meta-Analysis

Objective：To assess the association between X-ray repair cross-complementating group 1 （XRCC1） polymorphisms and pancreatic cancer.Methods：We searched MEDLINE,Web of Science and HuGE Navigator at June 2010,and then quantitatively summarized associations of the XRCC1 polymorphisms with pancreatic cancer risk using meta-analysis.Results：Four studies with 1343 cases and 2302 controls were included.Our analysis found：at codon 194,the Trp allele did not decrease pancreatic cancer risk （Arg/Arg versus Trp/Trp：OR=0.97;95% CI：0.48-1.96;P=0.97;Arg/Arg versus Arg/Trp：OR=0.89;95% CI：0.70-1.13;P=0.55;Arg/Trp versus Trp/Trp：OR=1.06;95% CI：0.52-2.16;P=0.90）;at codon 280,only a study showed a nonsignificant association between single nucleotide polymorphism with pancreatic cancer risk;at codon 399,the Gln allele also showed no signi？cant effect on pancreatic cancer compared to Arg allele （Arg/Arg versus Gln/Gln：OR=0.94;95% CI：0.74-1.18;Arg/Arg versus Arg/Gln：OR=0.97;95% CI：0.83-1.13;Arg/Gln versus Gln/Gln：OR=0.97;95% CI：0.77-1.22）.The shape of the funnel plot and the Egger＇s test did not detect any publication bias.Conclusion：There is no evidence that XRCC1 polymorphisms （Arg194Trp,Arg280His,and Arg399Gln） are associated with pancreatic cancer risk.

TP53 Arg72Pro and CCND1 A870G Polymorphisms and Esophageal Cancer Risk

The authors examined 184 residents from Kazakhstan to reveal an association of the CCND1 gene A870G and TP53 gene Arg72Pro polymorphisms with esophageal cancer risk. 86 of them were control group and 98 were patients with esophageal cancer. DNA samples were genotyped by direct sequencing method and TaqMan allelic discrimination method. Statistical analysis was performed using GraphPad InStatTM Software and ＂Case-Control Study Estimating Calculator＂ from TAPOTILI company. A significant association was revealed between CCND1 homozygous genotype （A870A, OR=2.654） and TP53 heterozygous （Arg72Pro, OR= 1.417） and homozygous （Pro72 Pro, OR=2.860） genotypes increased risk of esophageal cancer.

Meta-analysis of relationship between CYP2E1 and ALDH2 polymorphisms and hepatocellular carcinoma risk

The cytochrome P450 2El （ CYP2E1 ） and aldehyde dehydrogenase 2 （ALDH2） have been demonstrated that they were related to the development of hepatocellular carcinoma （HCC）. However, the associations have not been explained conclusively, and the combined analysis with the CYP2E1 Rsa I polymorphism and the ALDH2 pol- ymorphism have not been clarifed. In this study, we performed a meta-analysis to interpret the association between CYP2E1 and ALDH2 polymorphisms and HCC risk. Published literatures were retrieved from PubMed and Embase up to July, 2014. The pooled odds ratio （OR） with 95% confidence interval （CI） was calculated by using fixed- effects or random-effects model. A total of twelve case-controlled studies with 1 077 cancer cases and 2 000 controls concerning the CYP2E1 polymorphism were selected for this meta-analysis. The results indicated that there was no significantly associations between CYP2E1 polymorphism and risk of HCC （cl/c2 vs el/el ： OR - 1.11, 95% CI： 0.88-=1.39, P-0.38; c2/c2 vs el/el. OR -0.90, 95% CI. 0.54-=1.50, P-0.69; cl/c2 ＋ c2/c2 vs el/ el ： OR - 1.07, 95% CI： 0.89 -~ 1.30, P -0.47）. Further analysis of subgroup based on the ethnicity also showed no statistically significant associated with risk of HCC between the East Asians and the Europeans. In addi- tion, eight studies including 911 cases and 1 903 controls were included in this meta-analysis about the association between ALDH2 polymorphism and HCC risk. Results Based on our study also showed no significant association between ALDH2 polymorphism and the risk of HCC risk （ ＊ 1/＊ 2 vs ＊ 1/＊ 1： OR -0. 92, 95% CI： 0.65 -＊ 1.32, P-0.66; ,2/,2 vs ＊ 1/＊ 1. OR -0.82, 95% CI. 0.57-=1.18, P-0.28, ＊ 1/,2 ＋ ,2/,2 vs ＊ 1/＊ 1 ： OR -0.90, 95% CI. 0. 63 -- 1.29, P -0. 57）. The present meta-analysis indicated that there was no sig- nificant association between CYP2E1 polymorphism or ALDH2 polymorphism and HCC risk in the East Asians and the Europeans.

No association between the GSTM1 and GSTT1 polymorphism and endometrial cancer risk: A meta-analysi

Purpose: A number of case-control studies have been conducted to investigate the association of glutathione S-transferase (GST) genetic polymorphisms and endometrial carcinoma risk. However, these studies have yielded contradictory results. We therefore performed a meta-analysis to derive a more precise estimation of the association between polymorphisms on GSTM1, GSTT1 and endometrial carcinoma. Methods: Identification of relevant studies was carried out through a search in the following databases Medline, EMbase andChinaNational Knowledge International (CNKI) up to March. 2013. All case-control studies that investigated the association between GS-TM1 and GSTT1 gene polymorphisms and risk of endometrial cancer were included in the study. The pooled odds ratio (OR) was used for analyses of results and the corresponding 95% confidence intervals (CI) were estimated. Result: Six published case-control studies of association between the GSTM1 and GSTT1 polymorphism and endometrial cancer risk covering 3558 subjects were included in the metaanalysis, but the results indicated that the null genotypes of GSTM1 and GSTT1 polymorphisms were not associated with a significantly increased risk of endometrial cancer (for GSTM1: OR = 0.99;95% CI, 0.86 - 1.4;for GSTT1: OR = 0.96;95% CI, 0.80 - 1.14, respectively). Conclusion: This meta-analysis suggests that GSTM1 and GSTT1 polymorphism may not be associated with increased risk of endometrial cancer. To validate the association between polymorphism and endometrial cancer, further studies with larger numbers of participants worldwide are needed.

Association of hypoxia-inducible factor-1α (HIF1α) 1772C/T genepolymorphism with susceptibility to renal cell carcinoma/prostatecancer

In this study,we used a meta-analysis method to evaluate the relationship between hypoxia-inducible factor-1α(HIF1α)1772C/T gene polymorphism(rs 11549465)and renal cell carcinoma(RCC)/prostate cancer risk.We searched for relevant studies(before March 1,2019)on Cochrane Library,Embase,and PubMed.Studies meeting the inclusion criteria were recruited into this meta-analysis.The outcome of dichotomous data was showed in the way of odds ratios(OR),and 95%confidence intervals(CI)were also counted.In this investigation,there was no association between HIF1α1772C/T gene polymorphism and susceptibility to RCC in Caucasians,Asians as well as overall populations.In addition,HIF1α1772C/T gene polymorphism was not found to be relevant to the survival in RCC.Interestingly,the T allele was relevant to prostate cancer risk in all populations,but not in Caucasians and Asians.However,the TT genotype and the CC genotype were not related to prostate cancer susceptibility in Asian,Caucasian,and all populations.In conclusion,the T allele of the HIF1α1772C/T gene polymorphism was related to prostate cancer risk in the overall populations.

NQO1 Pro187Ser Polymorphism Confers to the Susceptibility of Prostate Cancer

Increasing epidemiological studies were recently performed to assess the relationship of NAD(P)H: quinine oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of prostate cancer (PCa) to yield inconsistent results. In this study, we aimed to generate large-scale evidence on whether NQO1 Pro187Ser polymorphism conferred to the susceptibility of PCa. The database of PubMed was comprehensively reviewed until September 12th, 2013, without any linguistic limitation. Meta-analysis was complied in the codominant, dominant, recessive and allele models by either fixed or random effect models. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of the association between the two. Finally, six eligible studies with 717 cases and 1764 controls were included. In overall analyses, significant associations were found in the dominant (OR = 1.26, 95%CI = 1.04 - 1.52, P = 0.02), allele (OR = 1.20, 95%CI = 1.03 - 1.40, P = 0.02) and the heterozygous codominant (OR = 1.24, 95%CI = 1.02 - 1.52, P = 0.03) models. Also, significant results were found in the stratified analyses by Hardy-Weinberg equilibrium (HWE). Still, subgroup analysis showed an increased risk of PCa in Asian rather than Caucasian population. Besides, NQO Pro187Ser polymorphism correlated with a heightened risk of PCa in the hospital-based studies. Our study indicated that NQO1 functional Pro187Ser polymorphism could be a potentially genetic biomarker for the risk of PCa, especially in Asian population.

Excision repair cross complementation group 1 polymorphisms and lung cancer risk： a meta-analysis

Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 （ERCC1） enzyme and lung cancer risk in diverse populations but with conflicting results.By pooling the relatively small samples in each study, it is possible to perform a meta-analysis of the evidence by rigorous methods.Methods Embase, Ovid, Medline and Chinese National Knowledge Infrastructure were searched. Additional studies were identified from references in original studies or review articles. Articles meeting the inclusion criteria were reviewed systematically, and the reported data were aggregated using the statistical techniques of meta-analysis.Results We found 3810 cases with lung cancer and 4332 controls from seven eligible studies. T19007C polymorphism showed no significant effect on lung cancer risk （C allele vs. T allele： odds ratio （OR）=0.91, 95% confidence interval （CI）=0.80-1.04; CC vs. TT： OR=0.76, 95% CI=0.56-1.02; CC vs. （CT＋TT）： OR=0.96, 95% CI=-0.84-1.10）. Similarly,there was no significant main effects for T19007C polymorphism on lung cancer risk when stratified analyses by ethnicity （Chinese or Caucasian）. No significant association was found between C8092A polymorphism （3060 patients and 2729 controls） and the risk of lung cancer （A allele vs. C allele： OR=1.03, 95% CI=0.95-1.11; AA vs. CC： OR=1.08, 95% CI=-0.88-1.33; AA vs. （AC＋CC）： OR=1.08, 95% CI=-0.88-1.31）.Conclusion We found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people.

基质金属蛋白酶-1启动子基因多态性与口腔癌易感性的Meta分析

目的:应用Meta分析方法研究基质金属蛋白酶MMP-1-1607 bp 1G/2G多态性和口腔癌易感性的关系。方法:检索各大数据库中符合纳入MMP-1-1607 bp 1G/2G启动子基因多态性与口腔癌易感性关系的病例对照研究,在各种不同遗传模型中进行对比,基因多态性与易感性的关系用比值比(OR)及95%可信区间(CI)表示,应用Rev Man 5.3软件对数据进行分析。结果:共纳入5篇研究,基于随机效应模型的Meta分析发现,1G/2G VS.2G/2G遗传模型OR=0.80,95%CI为0.53-1.20;1G VS.2G遗传模型OR=0.77,95%CI为0.54-1.11;2G/2G VS.1G/2G+1G/1G遗传模型OR=1.34,95%CI为0.87-2.06;1G/1G VS.1G/2G+2G/2G遗传模型OR=0.69,95%CI为0.36-1.36.结论:目前的文献尚不能证明MMP-1-1607 bp 1G/2G多态性和口腔癌易感性相关。